A randomized controlled phase III study comparing hadrontherapy with carbon ions versus conventional radiotherapy – including photon and proton therapy – for the treatment of radioresistant tumors: The ETOILE trial

Randomized controlled phase III trial to investigate superiority of robot-assisted gastrectomy over laparoscopic gastrectomy for clinical stage T1-4aN0-3 gastric cancer patients (JCOG1907, MONA LISA study): A study protocol

7 p | 5 | 4

Hypofractionated stereotactic radiotherapy (HFSRT) versus single fraction stereotactic radiosurgery (SRS) to the resection cavity of brain metastases after surgical resection (SATURNUS): Study protocol for a randomized phase III trial

10 p | 2 | 2

A novel carbon-fibre adjustable reusable accessory (CARA) for supine breast positioning to reduce toxicity in breast adjuvant radiotherapy: A study protocol for a multicentre phase III randomized controlled trial

14 p | 12 | 2

POstmastectomy radioThErapy in NodeposiTive breast cancer with or without Internal mAmmary nodaL irradiation (POTENTIAL): A study protocol for a multicenter prospective phase III randomized controlled trial

10 p | 9 | 2

A randomized phase III study of shortcourse radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII)

8 p | 9 | 1

Study protocol of REGOSARC trial: Activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial

10 p | 11 | 1

The ASAMET trial: A randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients

9 p | 13 | 1

Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): Study protocol for a phase III randomized controlled trial

7 p | 10 | 1

Establishing the quantitative relationship between Lanreotide autogel®, chromogranin A, and progression-free survival in patients with nonfunctioning gastroenteropancreatic neuroendocrine tumors

10 p | 15 | 0